Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24675580 | 1.00 | ACACB (0.52) | ACACBL3MBTL1GAANPSR1ACACA | |
| SCHEMBL29822969 | 0.86 | PPARA (0.46) | ACACBL3MBTL1GAAACACACTSK | |
| SCHEMBL9392681 | 0.86 | GAA (0.44) | ACACBL3MBTL1GAANPSR1HPGD | |
| SCHEMBL24674842 | 0.86 | PPARA (0.46) | ACACBL3MBTL1GAAACACACTSK | |
| SCHEMBL16805949 | 0.86 | GAA (0.46) | GAANPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL27225866 | 0.85 | ALDH1A1 (0.54) | ACACBMAPK1SMN1; SMN2CTSK | |
| SCHEMBL256390 | 0.84 | ACACB (0.64) | ACACBACACAHPGDLMNA | |
| SCHEMBL25534610 | 0.82 | SMN1; SMN2 (0.47) | ACACBGAALMNASMN1; SMN2CTSK | |
| SCHEMBL163496 | 0.81 | ACACB (0.77) | ACACB | |
| SCHEMBL18611917 | 0.81 | ACACB (0.48) | ACACBL3MBTL1ACACAHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174637-A1 | DEGRADERS OF GRK2 AND USES THEREOF | PIIZZI GRAZIA (US) | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174637-A1 | DEGRADERS OF GRK2 AND USES THEREOF | GRK2, GRK3, GRK1 | ACACB 3323/4885L3MBTL1 2436/4885GAA 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.